NCT05070247 2026-01-22A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTakedaPhase 1/2 Terminated61 enrolled 29 charts
NCT02538510 2024-11-26Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by SurgeryUniversity of WashingtonPhase 1/2 Completed50 enrolled 13 charts
NCT03769467 2024-11-14Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Atara BiotherapeuticsPhase 1/2 Terminated12 enrolled 8 charts
NCT03682055 2023-08-15Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)Cullinan Therapeutics Inc.Phase 1/2 Terminated14 enrolled 13 charts
NCT01806675 2019-10-0318F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyStanford UniversityPhase 1/2 Completed25 enrolled 14 charts